AbbVie buying Allergan in $63B deal for its post-Humira future
AbbVie will acquire Allergan in a $63B deal, answering questions over the company’s future beyond its top-selling drug Humira. Combined, the companies would rank as one of the industry’s largest pharmas.
This agreement follows several years of clinical setbacks and M&A missteps for Allergan. It also comes less than four years after an attempt by Pfizer to merge with Allergan in a $160B deal that was called off due to changes in U.S. tax rules. Since then, industry consolidation has continued, most recently with the Bristol-Myers Squibb’s $74B takeover of Celgene.
